SANA · Sana Biotechnology, Inc. · Executive Compensation
$2.35
-0.01 (-0.42%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$706.49M
Shares
299.36M
Volume · Oct 21
2.4M
Avg daily vol (3M)
3.21M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Steven D. Harr | President, Chief Executive Officer, and Director | $2,903,010 |
| Bernard J. Cassidy | Former Executive Vice President, General Counsel, and Corporate Secretary | $1,016,113 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Steven D. Harr | President, Chief Executive Officer, and Director | $8,788,580 |
| Nathan Hardy | Former Executive Vice President, Chief Financial Officer | $3,050,230 |
| Douglas E. Williams | Former Executive Vice President and President, Research and Development | $2,754,070 |
| Bernard J. Cassidy | Executive Vice President, General Counsel, and Corporate Secretary | $2,345,597 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Douglas E. Williams | Former Executive Vice President and President, Research and Development | $3,044,751 |
| Steven D. Harr | President, Chief Executive Officer, and Director | $2,671,662 |
| Nathan Hardy | Former Executive Vice President, Chief Financial Officer | $1,185,767 |
| Bernard J. Cassidy | Executive Vice President, General Counsel, and Corporate Secretary | $987,382 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Bernard J. Cassidy | Executive Vice President, General Counsel, and Corporate Secretary | $3,954,327 |
| Steven D. Harr | President, Chief ExecutiveOfficer, and Director | $3,807,979 |
| Sunil Agarwal | Former Executive Vice President, Head of Development, and Chief Medical Officer | $1,659,608 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sunil Agarwal | Former Executive Vice President, Head of Development, and Chief Medical Officer | $1,928,519 |
| Steven D. Harr | President, Chief ExecutiveOfficer, and Director | $1,186,154 |
| Nathan Hardy | Executive Vice President, Chief Financial Officer | $683,493 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Steven D. Harr | President, Chief Executive Officer, and Director | $6,845,197 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Steven D. Harr, M.D. | Class III director | Appointed | 2026-04-24 |
| Steven D. Harr, M.D. | Class I director | Resigned | 2026-04-24 |
| Brian Piper | Treasurer and Principal Financial Officer | Appointed | 2026-02-17 |
| Brian Piper | Executive Vice President, Chief Financial Officer | Appointed | 2026-02-17 |
| Aaron M. Grossman | Executive Vice President, Chief Legal Officer | Appointed | 2025-09-05 |
| Bernard J. Cassidy | Executive Vice President, General Counsel, and Corporate Secretary | Retired | 2025-09-05 |
| Mary Agnes Wilderotter | member of the Audit Committee of the Board | Resigned | 2025-08-29 |
| Mary Agnes Wilderotter | Board of Directors | Resigned | 2025-08-29 |
| Susan Wyrick | Acting Chief Financial Officer, Treasurer, and PAO | Appointed | 2024-10-08 |
| Steven D. Harr | acting Principal Financial Officer ("PFO") | Appointed | 2024-10-08 |
| Nathan Hardy | Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer ("PFO"), and Principal Accounting O | Resigned | 2024-10-08 |
| Nathan Hardy | Executive Vice President and Chief Financial Officer | Resigned | 2024-09-12 |
| Douglas Williams | Executive Vice President and President, Research and Development | Resigned | 2024-04-18 |
| Sunil Agarwal, M.D. | Executive Vice President, Head of Development, and Chief Medical Officer | Resigned | 2023-04-10 |
| Douglas E. Williams, Ph.D. | Executive Vice President and President, Research and Development | Appointed | 2023-04-10 |
Leadership
- Brian Piper CFO
- Steven D. Harr CFO
- Steven D. Harr, M.D. CFO, Board Member
- Susan Wyrick CFO
- Aaron M. Grossman General Counsel
- Alise S. Reicin Board Member
- Hans E. Bishop Board Member
- Robert Nelsen Board Member
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
16 filings
16 filers
Visit website
Investor relations